-
Innovation Ranking
NewInnovation Ranking – Pulse Biosciences Inc
Pulse Biosciences Inc (Pulse Biosciences) is a clinical-stage electroceutical company. It offers pursuing applications of its novel and proprietary Nano-Pulse Stimulation technology. The company carries out development of novel and proprietary platform technology called Nano-Pulse Electro-Signaling (NPES) for clinical applications. Its NPES is a local and drug-free treatment that utilizes nanosecond pulsed electric fields to induce cell signaling and activate cellular pathways in tissue. Pulse Biosciences’ NPES technology is used in applications such as dermatology, oncology, minimally invasive treatments, aesthetics...
-
Sector Analysis
Pulse Oximeter Systems Market Size by Segments, Share, Regulatory, Reimbursement, Installed Base and Forecast to 2033
Pulse Oximeter Systems Market Report Overview The pulse oximeter systems market size was valued at $1.37 billion in 2023 and will grow at a CAGR of more than 3% during the forecast period 2023 and 2033. Factors such as improved functions and user-friendly design will boost the pulse oximeter system demand. A pulse oximeter system is a photoelectric instrument that measures the oxygen saturation of blood noninvasively and continuously. They are commonly used in the operating room during procedures requiring...
-
Product Insights
NewCardiac Ablation Devices Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Cardiac Ablation Devices Pipeline Market Report Overview Cardiac ablation devices use radiofrequency energy to destroy cardiac tissues which propagate incorrect electrical signals to cause an abnormal heart rhythm. The cardiac ablation devices pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated...
-
Product Insights
Pennsylvania PULSE Solar PV Park
Pennsylvania PULSE Solar PV Park is a solar PV project located in Pennsylvania, United States. The project is owned and being developed by Lightsource BP Renewable Energy Investments Ltd. The project is at the permitting stage. Empower your strategies with our Pennsylvania PULSE Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding...
-
Product Insights
NewLikelihood of Approval Analysis for Paraganglioma (Glomus Jugulare Tumor)
Overview How likely is it that the drugs in Paraganglioma (Glomus Jugulare Tumor) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Paraganglioma (Glomus Jugulare Tumor) Overview Abnormal growth of chromaffin cells,...
-
Product Insights
NewLikelihood of Approval Analysis for Bacterial Pneumonia
Overview How likely is it that the drugs in Bacterial Pneumonia will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bacterial Pneumonia Overview Bacterial pneumonia is a lung infection caused by bacteria...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Multi-epitope (ME) T-cell Receptor Alternate Reading Frame Protein (TARP) Vaccine in Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Multi-epitope (ME) T-cell Receptor Alternate Reading Frame Protein (TARP) Vaccine in Prostate Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Multi-epitope (ME) T-cell...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cellular Immunotherapy To Target HER-2 For Oncology in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cellular Immunotherapy To Target HER-2 For Oncology in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cellular Immunotherapy To Target...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cellular Immunotherapy To Target HER-2 For Oncology in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cellular Immunotherapy To Target HER-2 For Oncology in Metastatic Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cellular Immunotherapy To Target HER-2...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cellular Immunotherapy To Target HER-2 For Oncology in Ductal Carcinoma In Situ
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cellular Immunotherapy To Target HER-2 For Oncology in Ductal Carcinoma In Situ report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cellular Immunotherapy To Target...